Alarming attrition rates among HIV-infected individuals in pre-antiretroviral therapy care in Myanmar, 2011–2014

Myo Minn Oo1*, Vivek Gupta2,3,4, Thet Ko Aung1, Nang Thu Thu Kyaw3, Htun Nyunt Oo5 and Ajay MV Kumar2,3

1International Union Against Tuberculosis and Lung Disease, Mandalay, Myanmar; 2International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, New Delhi, India; 3International Union Against Tuberculosis and Lung Disease, Paris, France; 4Community Ophthalmology, Dr. RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; 5National AIDS Program, Ministry of Health, Myanmar

Background: High retention rates have been documented among patients receiving antiretroviral therapy (ART) in Myanmar. However, there is no information on human immunodeficiency virus (HIV)-infected individuals in care before initiation of ART (pre-ART care). We assessed attrition (loss-to-follow-up [LTFU] and death) rates among HIV-infected individuals in pre-ART care and their associated factors over a 4-year period.

Design: In this retrospective cohort study, we extracted routinely collected data of HIV-infected adults (>15 years old) entering pre-ART care (June 2011–June 2014) as part of an Integrated HIV Care (IHC) programme, Myanmar. Attrition rates per 100 person-years and cumulative incidence of attrition were calculated. Factors associated with attrition were examined by calculating hazard ratios (HRs).

Results: Of 18,037 HIV-infected adults enrolled in the IHC programme, 11,464 (63%) entered pre-ART care (60% men, mean age 37 years, median cluster of differentiation 4 (CD4) cell count 160 cells/μL). Of the 11,464 eligible participants, 3,712 (32%) underwent attrition of which 43% were due to deaths and 57% were due to LTFU. The attrition rate was 78 per 100 person-years (95% CI, 75–80). The cumulative incidence of attrition was 70% at the end of a 4-year follow-up, of which nearly 90% occurred in the first 6 months. Male sex (HR 1.5, 95% CI 1.4–1.6), WHO clinical Stage 3 and 4, CD4 count <200 cells/μL, abnormal BMI, and anaemia were statistically significant predictors of attrition.

Conclusions: Pre-ART care attrition among persons living with HIV in Myanmar was alarmingly high – with most attrition occurring within the first 6 months. Strategies aimed at improving early HIV diagnosis and initiation of ART are needed. Suggestions include comprehensive nutrition support and intensified monitoring to prevent pre-ART care attrition by tracking patients who do not return for pre-ART care appointments. It is high time that Myanmar moves towards a ‘test and treat’ approach and ultimately eliminates the need for pre-ART care.

Keywords: pre-ART care; retention; lost to follow-up; death; SORT IT; operational research

Introduction

Globally, human immunodeficiency virus (HIV) infection continues to be an important infectious disease causing mortality and morbidity, particularly in developing countries. The burden of HIV in the Asia-Pacific region is high, with an estimated 4.9 million people living with HIV (PLHIV) (1). The number of PLHIV in Myanmar in 2013 was approximately 189,000 (2). Although HIV prevalence in Myanmar declined from 0.6% in 2010 to 0.5% in 2013, the burden in terms of absolute numbers remains high. In 2013, about 15,000 people died of AIDS-related causes and there were 7,000 new infections (1).

In 2011, Myanmar had about 90,000 patients who needed antiretroviral therapy (ART) (based on cluster of differentiation 4 CD4 cell counts less than 200 cells/μL), and 40,128 (44%) of them were receiving ART. Access to ART care in the country increased in 2012 with the National AIDS Programme (NAP) adopting the revised
World Health Organization-2010 (WHO) recommendations of increasing the CD4 threshold for ART initiation to 350 cell/mm$^3$ (2, 3). These recommendations increased the needs for ART care in Myanmar to 125,333 patients. Although overall ART coverage was 43%, 53,709 new patients commenced ART as a result of the change in recommendations. Once treatment started, these patients were actively followed up by the health system, and retention rates were fairly high (4). A study from Myanmar published in 2014 reported that nearly three-quarters of the HIV-infected patients receiving ART were still in care after 5 years (5).

Although retention is high among patients who have started ART, there is no information about the retention of those in pre-ART care, that is, care before initiation of ART. Studies from India and Africa show that pre-ART care attrition could be as high as 40% at 1 year after registration (5–8). Anecdotal evidence suggests that this could be similar in Myanmar, although prior to this study there was no clear evidence of this.

Myanmar is currently developing National Strategic Plans with the aim of achieving 90-90-90 goals related to HIV (diagnosing 90% of all PLHIV, treating 90% of those diagnosed, and achieving viral suppression in 90% of those treated) and finally ending the HIV/AIDS pandemic in line with the United Nations’ Sustainable Development Goals by 2030 (9). Hence, it is important to understand the outcomes among PLHIV in pre-ART care. Thus, among PLHIV enrolled in pre-ART care during 2011–2015 as part of the IHC programme in Myanmar, we aimed to assess attrition rates (loss-to-follow-up [LTFU] and death) and the socio-demographic and clinical factors associated with attrition.

**Methods**

**Ethics**
The Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, approved the study and waived the need for individual informed consent because the study involved a review of existing programme records. The NAP of Myanmar permitted us to use the data for publication. To ensure confidentiality, we excluded patient identifiers from the final database prior to analysis.

**Study design**
This is a retrospective cohort study using routinely collected data.

**Study setting**
The IHC programme is being implemented within the public sector by The Union, in collaboration with the Department of Health, National Tuberculosis (TB) Programme (NTP) and NAP since 2005 in Myanmar. Initial implementation was at a single ART clinic in Mandalay. Since then, there has been a steady expansion of the programme, and currently, ART is delivered through 18 ART centres and 14 ART decentralized sites. By the end of 2014, more than 20,000 patients were receiving ART in the IHC programme running across the country. Every month, around 400 patients are enrolled in the programme. Patients with a confirmed HIV diagnosis are referred from hospitals and health centres, STD (sexually transmitted disease)/HIV-AIDS clinics, TB clinics, antenatal clinics and ART programmes run by other organizations apart from the IHC.

Patient flow and assessment procedures after enrolment in IHC programme as well as the potential points of attrition in pre-ART care are shown in Fig. 1. Details of follow-up care of patients on ART have been previously published (5). After the patients are enrolled, they receive ART if they are eligible based on clinical or immunological criteria. Eligibility criteria for ART initiation are WHO clinical staging 3 or 4, and/or CD4 counts less than the threshold (200 cells/µL before 2012 and 350 cells/µL after 2012) (4, 10). For all enrolled patients, a second visit is needed to assess the results of CD4 count and other laboratory investigations for completion for ART eligibility evaluation. If patients do not come for a second visit within 6 weeks of enrolment, they are classified as ‘not assessed for eligibility at enrolment’. If the patient’s baseline CD4 is higher than the threshold or did not fall under WHO clinical Stage 3 or 4, she/he is categorized at the second visit as ‘not eligible for ART at enrolment’. There are patients who are eligible but are not initiated on ART within 6 weeks due to other reasons (deaths, LTFU due to social or economic reasons and patient refusal to start ART). These patients are categorized as ‘not started on ART at enrolment’. As shown in Fig. 1, PLHIV not assessed for eligibility, not eligible for ART, and not started on ART at enrolment are operationally defined here as ‘patients under the pre-ART care’. They are the patients who needed to be followed up for either completion of assessment, reassessment for eligibility, or for the earliest possible initiation of ART, respectively.

The PLHIV who are assessed and are not yet eligible for ART are usually clinically healthy and receive multivitamins, drugs for treatment of opportunistic infections, and counselling for psychosocial support. These patients are followed up after 3 months when ART eligibility is reassessed using the same clinical and immunological criteria described above. Subsequent follow-up visits of patients in pre-ART care usually occur at 6 monthly intervals but may be more frequent as per the discretion of the treating physician and as per patient needs.

The PLHIV who are eligible for ART but have not yet started on treatment are usually ill and hence prioritized
for receiving the next appointment in 1 or 2 weeks’ time. Patients who are not assessed for eligibility at enrolment are also scheduled for next appointment depending on their clinical condition. All of these services are provided free of cost to the patients.

The PLHIV taking ART in IHC programme are also involved as volunteers, actively participating in clinic activities such as triage, registration, adherence counseling, and psychosocial support, and they play an important role in tracing patients who are lost to follow-up. Most of these efforts are targeted towards those already on ART and incorrect addresses pose major problems. Reasons include a migratory population, fear of discrimination, and long travel distances to receive care.

Every patient has a dedicated file in which clinical details are entered by the treating doctors in IHC clinics. Data in these records are electronically captured in ‘IUATLD epi-concept’ database on a daily basis by trained data entry operators and medical doctors. Data quality control is performed at regular intervals to minimize errors in data entry and ensure data validity and consistency.

**Study population**

We included all HIV-infected adults (>15 years of age) enrolled into pre-ART care of IHC programme, Myanmar, between 1st June 2011 and 30th June 2014. We excluded patients aged ≤15 years and women under a prevention of mother-to-child transmission (PMTCT) programme because of the different follow-up and clinical management schedule. Patients transferred out to other ART facilities were also excluded.

**Data collection**

Data variables for demographic, clinical, and immunological characteristics included age, sex, marital status, literacy, employment, baseline WHO clinical staging, CD4 count, body mass index (BMI: defined as body weight in kilograms divided by the square of their height in meter [kg/m²]), haemoglobin level, and dates of enrolment, ART initiation, LTFU, last appointment, and hepatitis B and C infection status at enrolment. Based on haemoglobin (grams per decilitre) level, we divided the patients into four categories: normal (male, ≥13; female, ≥12), mild (male, 11–12.9; female, 11–11.9), moderate (both sexes, 8–10.9), and severe anaemia (both sexes, <8) (11). Data for these variables were extracted from the ‘IUATLD epi-concept’ database and exported for analysis. Patient records were anonymized and de-identified prior to analysis.

Outcomes of HIV-infected adults who entered pre-ART care in IHC programme are shown in Fig. 1. There were four operationally defined outcomes: 1) ‘Retained in pre-ART care’ defined as not missing scheduled follow-up date, but not yet started on ART; 2) started on ART; 3) LTFU, defined as not coming for follow-up visit within the 90 days after the last scheduled appointment; and 4) death. Patients having outcomes of LTFUs and deaths were combined together when estimating ‘attrition’ as primary outcome measure because many of LTFUs might be unascertained deaths (12).

**Statistical analysis**

STATA (version 12.1 STATA Corp., College Station, TX, USA) was used for data analysis. The baseline

---

**Fig. 1.** Patient flow and assessment procedures for HIV-infected individuals after enrolment in IHC programme, Myanmar. IHC, Integrated HIV Care; ART, antiretroviral therapy.
demographic, clinical, and immunological characteristics of patients were analysed. Survival analysis was undertaken to analyse the hazards of attrition after enrolment. The risk time of patients in pre-ART care started on their date of enrolment. For patients who developed attrition events (i.e. death or LTFU), the last scheduled appointment date (i.e. patient was scheduled to come but did not turn up) was the date of failure event. The last scheduled appointment date (up to 31st December 2015) was the date of censoring for patients who were retained in follow-up. Patients who were initiated on ART were censored on the date of ART initiation. Overall and stratum-specific cumulative attrition rates (death rates and LTFU rates) were estimated and expressed as attrition per 100 person-years (PYs). The cumulative incidence of attrition at monthly intervals for the first 6 months and then yearly from year 1 onwards was calculated as the proportion of patients in the cohort who had undergone attrition by the end of each period of follow-up. Associations between demographic, clinical, and immunological characteristics and attrition were studied, after excluding patients with missing values. Log-rank tests and bivariate unadjusted hazard ratios (HRs) were calculated. Characteristics found statistically significant during bivariate analysis (p < 0.2) were entered into a Cox proportional hazard regression model, and adjusted HRs were calculated. Model selection was based on comparisons of change in model-2 log-likelihood in backward stepwise manner. Interaction between WHO Stage and CD4 counts was examined. Proportionality assumptions were tested using Schoenfeld residuals, log–log plots, and observed versus predicted survival plots. Kaplan–Meier survival curves (showing the cumulative incidence of attrition) across strata of key variables associated with attrition were plotted. Statistical significance was assessed at 5% probability of type-1 error and 95% confidence intervals (95% CI) were estimated for attrition rates and HRs.

Results
In total, 18,037 HIV-infected adults were enrolled during the reference period. Of these patients, 17,694 (98%) were assessed for ART eligibility and 15,919 (90%) were found ART eligible. Among the ART eligible, only 6,573 (41%) were started on ART at enrolment. Thus, a total of 11,464 patients had CD4 count more than 500 cells/µL, and 5,445 (47%) were started on ART at enrolment. Among these, 10 patients had invalid dates and were removed from our analysis.

The demographic, clinical, and immunological characteristics of the study group are shown in Table 1. About 25% were men, and the mean age (standard deviation) was 37 (10) years. Literacy levels were high at 88% (10,112), whereas 25% (2,881) participants were unemployed. Only 6,521 (57%) of participants were married with another 19% being single and 23% either widowed or separated. Nearly half were in WHO Stage 3 and median CD4 count was 160 cells/µL (interquartile range: 69–312); 874 (8%) patients had CD4 count more than 500 cells/µL. Nearly half had BMI of less than 18.5 kg/m² and two-thirds were anaemic. The proportion of missing records was high for CD4 count (15%), BMI (21%), and haemoglobin level (16%) (Table 1).

The pre-ART group had a total observation period of 4,788 PYs, during which 3,712 attrition events occurred: 1,585 (43%) deaths and 2,127 (57%) LTFU. The overall attrition rate was 78 per 100 PYs (95% CI, 75–80). Based on the nature of entry in the pre-ART cohort, the attrition rate among 343 patients not assessed for ART eligibility was 92 (95% CI, 77–110), 1,776 patients assessed for ART but not found eligible was 42 (95% CI, 39–45), and the 9,346 patients found ART eligible but not started was 98 (95% CI, 94–101) per 100 PYs. Of the patients entering pre-ART care, 7,261 (64.4%) were subsequently initiated on ART at a median follow-up time interval of 77 days.

The cumulative incidence of attrition and the nature of attrition are shown in Table 2. It was observed that 25% of the pre-ART cohort underwent attrition within the first 3 months. Nearly 90% of all attrition events occurred during the first 6 months of enrolment. Among attrition within the first month, the proportion due to deaths and LTFU were 40 and 60%, which changed to 51 and 49%, respectively, by the end of second month. The contribution of deaths to total attrition was high initially and decreased over time.

Stratum-specific attrition rates by patient characteristics and the estimated HRs for attrition are shown in Table 3. The highest attrition rates were observed among patients in WHO Stage 3 and 4, and among the severely anaemic. On bivariate analysis, the hazard of attrition was higher among patients who were male, aged >45 years, not married, illiterate, in WHO clinical Stage 3 or 4, had a CD4 count of less than 200 cell/µL, had BMI <25 kg/m², and had anaemia (Table 3). In a multivariate Cox proportional hazards model, being male, in WHO Stage 3, having a CD4 count less than 50 cell/µL, having a BMI <25 kg/m², and having moderate or severe anaemia, were factors independently associated with a higher risk of attrition. However, because the covariates, apart from the WHO staging, were found to violate the proportionality assumptions, the adjusted analysis results are not presented here. The unadjusted cumulative incidence of attrition by age, sex, WHO Stage, CD4 counts, BMI, and haemoglobin levels over the period of follow-up is presented in Fig. 3. Interaction between WHO Stage and the CD4 count was not statistically significant.

Discussion
This is the first study from Myanmar on pre-ART attrition among HIV-infected patients. Pre-ART patients are one of the most neglected subgroups of PLHIV. Attrition rates among pre-ART groups worldwide are
higher as compared to those receiving ART (5, 6, 13, 14). In Myanmar, within the IHC programme, an alarmingly high attrition rate was observed with nearly 70% being either dead or LTFU at the end of 4 years. This is one of the highest rates of attrition ever reported, in line with published reports from Asia and Africa (6–8) (15–21).

Most of the attrition occurred in the early stages of enrolment into care: 90% of attrition occurred within first 6 months with nearly half in the first month. This is worrisome and requires urgent attention. Although risk of attrition was higher among those with low CD4 counts and in WHO Stage 3 or 4, males, patients with low BMI, or those who are unmarried, attrition rates remained high across all strata. These findings are similar to those reported in previous studies (7, 8, 17, 18).

The median CD4 count was low at 160 cells/µL indicating advanced disease at presentation, delays in care seeking by PLHIV, and delayed diagnosis. This is possibly a reason for high dead cases during the first month. To address this, HIV testing should be made more widely available in the country. Currently, national guidelines in Myanmar recommend HIV testing of high-risk groups, pregnant women, new military recruits, and TB patients (4, 22). Efforts should be made to increase HIV test coverage in these groups. Another group to consider in regard to offering HIV testing is ‘presumptive TB patients’. Several studies have shown that HIV prevalence in this group is as high as that among TB patients suggesting the need for screening and early diagnosis of HIV (23).

Even among those found to be eligible for ART, more than half started on ART only 6 weeks after enrolment, suggesting delayed ART initiation. This might have contributed to the high mortality found in our study which is also in line with previous studies (24–27). The attrition rate in this group (eligible for ART) was the highest, when compared with those who were not assessed and those who were assessed but not eligible for starting ART.

It appears that starting a patient on ART is the best way of retaining patients in care (28, 29). We recommend starting all PLHIV diagnosed on ART irrespective of CD4 count or clinical stage in line with the recent WHO recommendation of ‘test and treat’ approach (30). It is encouraging to note that Myanmar NAP has already adopted the WHO-2013 guideline (CD4 threshold of 500)
since March 2015 (10, 22). With this, the proportion on pre-ART care will reduce substantially. Given this preparedness and because only 8% of PLHIV have CD4 counts of more than 500 thereby requiring ART, it might be feasible to ‘test and treat’ all with little additional burden on the programme.

Until the country moves into ‘test and treat’ strategy, we need to ensure that patients placed on pre-ART care are monitored well. We recommend introducing an indicator in the monthly report for monitoring retention and/or attrition among pre-ART cohort (31) because current reports in HIV care mostly focus on those receiving ART. Having an indicator showing how many patients are lost or died before starting on ART can give a clear view of how well we are doing before giving them ART. The care package currently provided (treatment for opportunistic infection, multivitamins, and counselling service) to pre-ART group needs to be strengthened by including provision of nutritional support and needs serious consideration because attrition is linked to low BMI and low haemoglobin. Currently, a number of patient visits (at least two and sometimes three to four) are required for full assessment and clinical decision-making. Steps, such as point-of-care CD4 testing and automated analyzers (32), have the potential to expedite assessment procedures and reduce the number of patient visits and the attrition that occurs during the process (6). Finally, we need to ensure that the systematic patient tracing systems are utilized for all patients and not limited only to those on ART. The systematic tracing system that is currently used for patients on ART who miss an appointed date includes tracing these patients every 2 weeks for 2 months and then monthly for 3 months until they come back or for a maximum of 7 months if they do not come back, using mobile phones or home visits by PLHIV volunteers.

**Strengths**

This study has several strengths. Firstly, the information is drawn from the second largest cohort of PLHIV in Myanmar with long follow-up data providing reliable estimates of attrition. Secondly, the data come from programmatic settings, thus reflecting the realities on the ground. Thirdly, this fills a knowledge gap in Myanmar about attrition among pre-ART care. Although there are many studies of ART cohorts, no previous study has examined pre-ART cohort in Myanmar (5). Fourthly, we used robust methods of data cleaning and analysis including multivariate survival analysis to examine factors associated with attrition. Finally, we followed the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines for conducting and reporting this research in a scientific and ethical manner (33, 34).

| Table 1. Demographic, clinical and immunological characteristics of HIV-infected adults who entered pre-ART care of the Integrated HIV Care (IHC) programme, Myanmar, 2011–2014 |

| Patient characteristics | Number (%) |
|-------------------------|------------|
| Sex                     |            |
| Female                  | 4,848 (42) |
| Male                    | 6,606 (58) |
| Age (years)             |            |
| 16–25                   | 699 (6)    |
| 25–34                   | 4,269 (37) |
| 35–44                   | 4,378 (38) |
| ≥ 45                    | 2,108 (18) |
| Marital status          |            |
| Single                  | 2,123 (19) |
| Married                 | 6,521 (57) |
| Widowed                 | 1,940 (17) |
| Divorced/separated      | 708 (6)    |
| Unknown                 | 162 (1)    |
| Literate                |            |
| No                      | 1,198 (10) |
| Yes                     | 10,112 (88)|
| Unknown                 | 144 (1)    |
| Employed                |            |
| No                      | 2,881 (25) |
| Yes                     | 8,228 (72) |
| Unknown                 | 345 (3)    |
| WHO Stage               |            |
| Stage 1                 | 2,609 (23) |
| Stage 2                 | 1,968 (17) |
| Stage 3                 | 5,220 (46) |
| Stage 4                 | 1,519 (13) |
| Unknown                 | 138 (1)    |
| CD4 count (cells/μL)    |            |
| < 50                    | 1,687 (15) |
| 50–99                   | 1,670 (15) |
| 100–199                 | 2,285 (20) |
| 200–349                 | 2,094 (18) |
| 350–499                 | 1,149 (10) |
| > 500                   | 874 (8)    |
| Unknown                 | 1,695 (15) |
| BMI (kg/m²)             |            |
| < 18.5                  | 3,871 (34) |
| 18.5–25                 | 4,262 (37) |
| 25–30                   | 618 (5)    |
| 30–35                   | 142 (1)    |
| > 35                    | 118 (1)    |
| Unknown                 | 2,443 (21) |
| Haemoglobin level       |            |
| Normal                  | 3,220 (28) |
| Mild anaemia            | 2,184 (19) |
| Moderate anaemia        | 3,285 (29) |
| Severe anaemia          | 951 (8)    |
| Unknown                 | 1,814 (16) |
| Hepatitis C infection   |            |
| No                      | 8,255 (72) |
| Yes                     | 769 (7)    |
| Unknown                 | 2,430 (21) |
| Hepatitis B infection   |            |
| No                      | 8,268 (72) |
| Yes                     | 751 (7)    |
| Unknown                 | 2,435 (21) |

*a* Measured at enrolment; HIV, human immunodeficiency virus; ART, antiretroviral therapy; 100 PYs, 100 person-years of observation; CI, confidence interval; WHO, World Health Organization; BMI, body mass index; Hb, haemoglobin.
Limitations

As always, there are some limitations and they are mainly related to the operational nature of this study. Firstly, we used a definition of 90 days after the last appointed date to define LTFU. Given that the visits in pre-ART care were scheduled to be between 3 and 6 months apart for clinically healthy patients, we had to wait for 6 to 9 months before declaring LTFU. Hence, it is possible that some of the patients categorized as ‘retention in pre-ART’ at the time of assessment could actually be LTFU or dead. Thus, we could be underestimating our attrition rates. On the other hand, it is possible that many of those identified as having dropped out could be receiving HIV care in other facilities, without our knowledge (6). Because there is no systematic tracking of the patients in pre-ART care, we do not know the magnitude of this crossover (6). LTFU contributed to more than half of this overall rate. As half of LTFU patients were actually reported as dead in one study (12), one could make an assumption that in fact, death rate might be higher.

Secondly, substantial proportions of missing data were found on some important variables such as CD4 count, body mass index, and haemoglobin levels, which were all measured at enrolment. A missing data analysis revealed that males were more likely to have missing data as compared to females. Younger participants too were more likely to have missing hepatitis B and hepatitis C results, whereas older participants are likely to have missing BMI and CD4 results. This is likely because of higher rates or early attrition among males. This could also be related to problems in documentation, which currently is mostly paper-based. A possible solution might be to institute a real-time web-based management information system with data entry at each clinic and laboratory. Thirdly, as the nature of paediatric or pregnant women under the PMTCT cohort and adult cohort are different, we cannot apply the findings of this study to these cohorts. Lastly, we did not explore the actual reasons behind attrition among pre-ART group in this study. A better understanding of these reasons warrants further research, especially using qualitative methods with in-depth interviews of patients, family members, and providers.

Conclusion

Attrition in a pre-ART HIV care cohort in Myanmar was alarmingly high – with most occurring within the first 6 months. Strategies such as improving early HIV diagnosis and the early initiation of ART, providing comprehensive nutrition support, implementing intensive monitoring using newly developed indicators, and tracking patients who do not return for their appointments are needed. It is most important that Myanmar moves towards universal ART and eliminate the need for pre-ART care.

Authors’ contributions

MMO, AMVK, and VG conceived and designed the experiment, performed statistical analysis, wrote the first draft of the article, incorporated comments, and finalized the article. NTTK, TKA, and HNO commented on drafts. All authors viewed, approved the final draft, and made the final decision to submit the article.

Open-access statement

In accordance with WHO’s open-access publication policy for all work funded by WHO or authored/co-authored
Table 3. Factors associated with attrition among HIV-infected adults who entered into pre-ART care in IHC programme, Myanmar, 2011–2014

| Patient characteristics | Attrition | Attrition rate per 100 person-years (95% CI) | Unadjusted hazard ratio (95% CI) |
|-------------------------|-----------|---------------------------------------------|----------------------------------|
| **Sex**                 |           |                                             |                                  |
| Female                  | 1,344     | 56.3 (53.4–59.4)                            | 1                                |
| Male                    | 2,368     | 98.7 (94.8–102.8)                           | 1.5 (1.4–1.6) a                  |
| **Age (years)**         |           |                                             |                                  |
| 15–24                   | 251       | 55.6 (49.2–63)                              | 1                                |
| 25–34                   | 1,348     | 65.7 (62.3–69.3)                            | 1 (0.9–1.2)                      |
| 35–44                   | 1,337     | 83.4 (79–87.9)                              | 1.1 (1.0–1.3)                    |
| ≥ 45                    | 776       | 114.1 (106.3–122.4)                         | 1.5 (1.3–1.7) a                  |
| **Marital status**      |           |                                             |                                  |
| Single                  | 758       | 97.5 (90.8–104.7)                           | 1.3 (1.2–1.4) a                  |
| Married                 | 1,996     | 66.9 (64.1–69.9)                            | 1                                |
| Widowed                 | 616       | 83.6 (77.2–90.5)                            | 1.1 (1.0–1.2) a                  |
| Divorced/separated      | 257       | 109.3 (96.7–123.5)                          | 1.4 (1.2–1.6) a                  |
| **Literate**            |           |                                             |                                  |
| No                      | 509       | 103.9 (95.3–113.4)                          | 1.5 (1.3–1.6) a                  |
| Yes                     | 3,119     | 73.3 (70.8–75.9)                            | 1                                |
| **Employed**            |           |                                             |                                  |
| No                      | 993       | 75.7 (71.1–80.5)                            | 1                                |
| Yes                     | 2,555     | 77.4 (74.5–80.5)                            | 1.1 (1–1.1) a                    |
| **WHO Stage** b         |           |                                             |                                  |
| Stage 1                 | 698       | 35.1 (32.6–37.8)                            | 1                                |
| Stage 2                 | 418       | 45.2 (41.1–49.8)                            | 1.1 (0.9–1.2)                    |
| Stage 3                 | 1,885     | 126.2 (120.6–132)                           | 2.4 (2.2–2.7) a                  |
| Stage 4                 | 597       | 165.5 (152.7–179.3)                         | 3.0 (2.7–3.3) a                  |
| **CD4 count (cells/μL)**|           |                                             |                                  |
| <50                     | 518       | 113.3 (104–123.5)                           | 3.4 (2.9–3.9) a                  |
| 50–99                   | 368       | 77.4 (69.8–85.7)                            | 2.3 (2–2.8) a                    |
| 100–199                 | 353       | 50.8 (45.7–56.4)                            | 1.5 (1.3–1.8) a                  |
| 200–349                 | 296       | 33.4 (29.8–37.4)                            | 1.1 (0.9–1.3)                    |
| 350–499                 | 281       | 28.5 (25.4–32.1)                            | 1.1 (0.9–1.2)                    |
| ≥500                    | 266       | 24.8 (22–28)                                 | 1                                |
| **BMI (kg/m²)** b       |           |                                             |                                  |
| <18.5                   | 1,117     | 82.2 (77.5–87.2)                            | 4.1 (2.4–7.1) a                  |
| 18.5–25                 | 839       | 37.5 (35–40.1)                              | 2.2 (1.3–3.7) a                  |
| 25–30                   | 100       | 28.2 (23.2–34.3)                            | 1.7 (1.0–3.1)                    |
| 30–35                   | 26        | 33.7 (23–49.5)                              | 2.1 (1.1–4.0) a                  |
| ≥35                     | 13        | 14.7 (8.5–25.3)                              | 1                                |
| **Haemoglobin level** b |           |                                             |                                  |
| Normal                  | 471       | 26 (23.7–28.4)                              | 1                                |
| Mild anaemia            | 383       | 35 (31.7–38.7)                              | 1.3 (1.2–1.5) a                  |
| Moderate anaemia        | 801       | 62.1 (58–66.6)                              | 2.2 (2.0–2.5) a                  |
| Severe anaemia          | 403       | 144.3 (130.9–159.1)                         | 4.8 (4.2–5.5) a                  |
| **Hepatitis C infection**|           |                                             |                                  |
| No                      | 1,737     | 46.8 (44.6–49)                              | 1                                |
| Yes                     | 186       | 52.9 (45.8–61)                              | 1.1 (1.0–1.3)                    |
| **Hepatitis B infection**|         |                                             |                                  |
| No                      | 1,764     | 46.8 (44.6–49)                              | 1                                |
| Yes                     | 156       | 52.9 (45.2–61.9)                             | 1.1 (0.9–1.3)                    |

*p*-value < 0.05; b measured at enrolment; † The final adjusted Cox-model was tried and included the covariates sex, age, WHO Stage, CD4 count, BMI, and haemoglobin levels. The results are not presented here as all covariates variables were found to violate proportionality assumptions.

HIV, human immunodeficiency virus; ART, antiretroviral therapy; HR, hazard ratio; BMI, body mass index; WHO, World Health Organization
Fig. 3. Cumulative incidence of attrition by age, sex, WHO Stage, CD4 counts, BMI and haemoglobin levels among patients who entered into pre-ART care, Myanmar, 2011–2014. WHO, World Health Organization; BMI, body mass index; ART, antiretroviral therapy; Norm., normal; Mod., moderate; Sev., severe; An., anaemia.
improvement, which could be improved by the initial failure to adhere to treatment. However, there are also some challenges unique to this setting, such as the high burden of non-communicable diseases and the lack of access to proper care for these conditions.

Acknowledgements

This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Programme for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Médecins Sans Frontières. The specific SORT IT programme, which resulted in this publication, was jointly developed and implemented by: The Union South-East Asia Regional Office, New Delhi, India; the Centre for Operational Research, The Union, Paris, France; the Union Against Tuberculosis and Lung Disease (The Union) and Médecins Sans Frontières. The Union Against Tuberculosis and Lung Disease (The Union) and Médecins Sans Frontières, Brussels Operational Center, Luxembourg; School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India; and the Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.

Conflict of interest and funding

None declared. The programme was funded by the Department for International Development (DFID), UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Paper context

High retention rates have been documented among patients receiving antiretroviral therapy (ART) in Myanmar. However, there is no information on HIV-infected individuals in pre-ART care making it the most neglected part of the HIV care chain. In this study, alarming high attrition (death or lost-to-follow-up) rates in pre-ART care were observed, especially within the first six months after registering for care. These results lend support to a strategy of ‘Test and Treat’ for all PLHIV in Myanmar.

References

1. UNAIDS (2013). HIV in Asia and the Pacific. Thailand: UNAIDS.
2. National AIDS Program, Ministry of Health Myanmar (2014). Global AIDS response progress report. Myanmar: National AIDS Program.
3. World Health Organization (2010). Antiretroviral therapy for HIV infection in adults and adolescents: recommendation for a public health approach. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html [cited 7 March 2015].
4. National AIDS Program, Ministry of Health Myanmar (2011). Guidelines for the clinical management of HIV infection in adults and adolescents in Myanmar. 3rd ed. Myanmar: National AIDS Program.
5. Thida A, Tun STT, Zaw SKK, Lover AA, Cavailler P, Chunh J, et al. Retention and risk factors for attrition in a large public health ART program in Myanmar: a retrospective cohort analysis. PLoS One 2014; 9: e108615. doi: http://dx.doi.org/10.1371/journal.pone.0108615
6. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8: e1001056. doi: http://dx.doi.org/10.1371/journal.pmed.1001056
7. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural Kwazulu-Natal, South Africa. J Acquir Immune Defic Syndr 2011; 56: 679–86. doi: http://dx.doi.org/10.1097/QAI.0b013e3182075ae2
8. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One 2010; 5: e13268. doi: http://dx.doi.org/10.1371/journal.pone.0013268
9. World Health Organization (2013). Health in 2015 from MDGs to SDGs. Geneva: World Health Organization.
10. World Health Organization (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available from: http://apps.who.int/iris/bitstream/10665/13219/1/9789241505727_eng.pdf [cited 7 March 2015].
11. Chan M. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: World Health Organization; 2011, pp. 1–6.
12. Brinkhof MWG, Pujades-Rodríguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4: e5790. doi: http://dx.doi.org/10.1371/journal.pone.0005790
13. Shankar D, Kumar AMV, Rewari B, Kumar S, Shastri S, Satyanarayana S, et al. Retention in pre-ART antiretroviral treatment care in a district of Karnataka, India: how well are we doing? Public Health Action 2014; 1: 210–15.
14. Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 2010; 15: 43–7. doi: http://dx.doi.org/10.1111/j.1365-3156.2010.02511.x
15. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51: 135–9. doi: http://dx.doi.org/10.1097/QAI.0b013e3181a44e2.
16. Ingle S, May M, Uebel K, Kotze E, Bachmann M, Sterne JAC, et al. Outcomes in patients waiting for antiretroviral treatment care in the free State Province, South Africa: prospective linkage study. AIDS 2011; 24: 2717–25. doi: http://dx.doi.org/10.1097/QAD.0b013e32833fb7f1/Outcomes
17. Karcher H, Omondi A, Oden J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow up in an antiretroviral treatment cohort in Trop Med Int Health 2007; 12: 687–94. doi: http://dx.doi.org/10.1111/j.1365-3156.2007.01830.x
18. Molfino L, Kumar AMV, Isaakidis P, Van den Bergh R, Khogali M, Hinderaker SG, et al. High attrition among HIV-infected patients with advanced disease treated in an intermediate referral center in Maputo, Mozambique. Glob Health Action 2014; 7: 23758. doi: http://dx.doi.org/10.3402/gha.v7.23758
19. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr 2013; 63: e64–71. doi: http://dx.doi.org/10.1097/QAI.0b013e31828af5a6
20. Castelnuovo B, Musaazi J, Musomba R, Ratanshi RP, Kiragga AN. Quantifying retention during pre-antiretroviral treatment
in a large urban clinic in Uganda. BMC Infect Dis 2015; 15: 252. doi: http://dx.doi.org/10.1186/s12879-015-0957-1

21. Shaweno T, Shaweno D. When are patients lost to follow-up in pre-antiretroviral therapy care? A retrospective assessment of patients in an Ethiopian rural hospital. Infect Dis Poverty 2015; 4: 27. doi: http://dx.doi.org/10.1186/s40249-015-0056-y

22. National AIDS Program, Ministry of Health Myanmar (2014). Guidelines for the clinical management of HIV infection in Myanmar. United Kingdom: BioMed Central.

23. Palanivel C, Kumar AMV, Mahalakshmi T, Govindarajan S, Claassens M, Satyanarayana S, et al. Uptake of HIV testing and HIV positivity among presumptive tuberculosis patients at Puducherry, South India. Public Health Action 2013; 3: 220–3. doi: http://dx.doi.org/10.5588/pha.13.0045

24. Hoffmann CJ, Lewis JJ, Dowdy DW, Fielding KL, Grant AD, Martinson NA, et al. Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr 2013; 63: 105–11. doi: http://dx.doi.org/10.1097/QAI.0b013e3182893fb4

25. Ndiaye B, Kacia K-O, Salleronb J, Bataille P, Bonnevied F, Cochonate K, et al. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS 2009; 23: 1786–9.

26. Pe R, Chim B, Thai S, Lynen L, van Griensven J. Advanced HIV disease at enrolment in HIV care: trends and associated factors over a ten year period in Cambodia. PLoS One 2015; 10: e0143320. doi: http://dx.doi.org/10.1371/journal.pone.0143320

27. Thai S, Koole O, Un P, Ros S, De Munter P, Van Damme W, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009; 14: 1048–58. doi: http://dx.doi.org/10.1111/j.1365-3156.2009.02334.x

28. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21: 2483–91. doi: http://dx.doi.org/10.1079/QAD.20013e328209876

29. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815–26. doi: http://dx.doi.org/10.1056/NEJMoa0807252

30. World Health Organization (2015). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Switzerland.

31. van Griensven J. Attrition of HIV-infected individuals not yet eligible for ART: why should we care? Trans Roy Soc Trop Med Hyg 2010; 104: 690–3.

32. Jani IV, Sitoe NE, Alfa ER, Chongo P, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378: 1572–9. doi: http://dx.doi.org/10.1016/S0140-6736(11)61052-0

33. STROBE (2007). STROBE 2007 (v4) Statement – Checklist of items that should be included in reports of cohort studies. Switzerland.

34. Edginton M, Enarson D, Zachariah R, Reid T, Satyanarayana S, Bissell K, et al. Why ethics is indispensable for good-quality operational research. Public Health Action 2012; 2: 21–2. doi: http://dx.doi.org/10.5588/pha.12.0001